medRxiv PreprintsInternational19 November 2026
lncSigAML: An AI-derived Long Non-coding RNA Prognostic Signature with Multi-Cohort Validation across 2,681 Patients with Acute Myeloid Leukemia
This is an official announcement record
Firsthand records what medRxiv Preprints announced and links to the original. The wording below is theirs, not ours.
Acute myeloid leukemia (AML) is clinically and genetically heterogeneous. Current risk stratification systems based on cytogenetic and genetic abnormalities do not fully capture prognostic heterogeneity, particularly among intermediate-risk patients. Long non-coding RNAs (lncRNAs) have emerged as key regulators of AML biology, contributing to leukemogenesis, impaired differentiation, apoptosis resistance, and treatment response. In this study, we developed we developed a bone marrow-derived lncRNA prognostic signature, termed lncSigAML, using in pediatric samples from TARGET-AML (n = 1,594) an
Read the official announcement
Opens www.medrxiv.org
More from medRxiv Preprints
- Unmet needs of Polish patients with cystic fibrosis seen through the lens of crowdfunding20 November 2026
- Motherly Plus: Study Protocol of a Randomized Controlled Trial Evaluating a Smartphone-Assisted Single-Session Psychotherapy Intervention for Postpartum Depression20 November 2026
- Targeting memory consolidation in major depression via pharmacological slow-wave sleep promotion20 November 2026
- Epidemiology of Cardiac Structure and Function Among African Caribbeans in Tobago: A Population-based Cohort Study20 November 2026
- Depressive Symptom Trajectories and Incident Cognitive Impairment by Outcome Ascertainment20 November 2026
This content is for informational purposes only and is not medical advice. It is not intended to diagnose, treat, cure, or prevent any disease. Consult a healthcare professional before starting any supplement, treatment, or program: especially if you are pregnant, nursing, taking medication, or managing a health condition.